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7RESEARCH Open AccessVesicular stomatitis virus replicon expressing the
VP2 outer capsid protein of bluetongue virus
serotype 8 induces complete protection of sheep
against challenge infection
Stefanie Kochinger, Nathalie Renevey, Martin A Hofmann and Gert Zimmer*Abstract
Bluetongue virus (BTV) is an arthropod-borne pathogen that causes an often fatal, hemorrhagic disease in ruminants.
Different BTV serotypes occur throughout many temperate and tropical regions of the world. In 2006, BTV serotype 8
(BTV-8) emerged in Central and Northern Europe for the first time. Although this outbreak was eventually controlled
using inactivated virus vaccines, the epidemic caused significant economic losses not only from the disease in livestock
but also from trade restrictions. To date, BTV vaccines that allow simple serological discrimination of infected and
vaccinated animals (DIVA) have not been approved for use in livestock. In this study, we generated recombinant RNA
replicon particles based on single-cycle vesicular stomatitis virus (VSV) vectors. Immunization of sheep with infectious
VSV replicon particles expressing the outer capsid VP2 protein of BTV-8 resulted in induction of BTV-8 serotype-specific
neutralizing antibodies. After challenge with a virulent BTV-8 strain, the vaccinated animals neither developed signs of
disease nor showed viremia. In contrast, immunization of sheep with recombinant VP5 - the second outer capsid
protein of BTV - did not confer protection. Discrimination of infected from vaccinated animals was readily achieved
using an ELISA for detection of antibodies against the VP7 antigen. These data indicate that VSV replicon particles
potentially represent a safe and efficacious vaccine platform with which to control future outbreaks by BTV-8 or other
serotypes, especially in previously non-endemic regions where discrimination between vaccinated and infected animals
is crucial.Introduction
Bluetongue is a hemorrhagic disease of ruminants that is
caused by bluetongue virus (BTV), a member of the genus
Orbivirus within the family Reoviridae [1-3]. BTV is trans-
mitted to livestock by blood-feeding Culicoides midges. In
cattle, goats, and wild ruminants, BTV infection is typi-
cally asymptomatic despite prolonged viremia. These host
species represent a potential reservoir for unnoticed dis-
semination of BTV in ruminant populations. In sheep,
however, BTV infection often results in an acute disease
with associated high morbidity and mortality, depending
on the virulence of the virus and the sheep breed affected
[4]. Typical symptoms of bluetongue in sheep include
high fever, tissue edema, hemorrhages, and necrosis of the* Correspondence: gert.zimmer@ivi.admin.ch
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article, unless otherwise stated.upper gastrointestinal tract as well as of skeletal and car-
diac musculature. Certain strains of BTV, notably the
northern European strain of BTV-8, can cross the placen-
tal barrier, leading to infection of the developing fetus [5].
Hence, infection of pregnant animals with certain strains
of the virus are frequently associated with abortions and
malformations of offspring [6-8].
The BTV genome consists of 10 segments of dsRNA,
which encode 7 structural (VP1 - VP7) and 5 non-struc-
tural proteins (NS1 – NS4, NS3a) [9]. The non-enveloped
icosahedral virion particle contains an inner core which is
formed by the viral RNA and the viral proteins VP1 (RNA
polymerase), VP4 (capping enzyme), and VP6 (helicase)
[10,11]. The inner core is surrounded by 3 concentric pro-
tein layers. The inner capsid layer consists of 120 copies of
VP3 arranged as 60 dimers that form a scaffold for VP7.
The outer capsid is composed of the viral proteins VP2tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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hemagglutination, and membrane penetration, respec-
tively [12,13]. The large (110 kDa) attachment protein
VP2 induces virus-neutralizing antibodies [14]. However,
VP2 is highly variable and currently 26 different BTV se-
rotypes can be distinguished by antibodies that show little
or no cross-neutralizing activity [3]. Binding of VP5 to
VP2 leads to a VP2 conformational change, which may
affect recognition of epitopes by neutralizing antibodies
[15,16]. All other structural and non-structural proteins
are relatively conserved among different BTV serotypes.
Therefore, most ELISAs for pan-BTV antibody detection
employ the VP7 antigen [17].
A novel strain of BTV serotype 8 (BTV-8), which had
not been detected in Europe before 2006, emerged as an
epidemic wave in Western and Northern Europe [3,18,19].
This outbreak had a significant economic impact, not only
because the disease caused morbidity and mortality in
sheep and cattle but also because of restrictions imposed
on livestock movement and trade [20]. The epizootic was
controlled by a large-scale vaccination campaign using
whole inactivated BTV-8. Although this vaccine induced
strong protection against BTV-8 infection and disease, it
did not allow the simple serological discrimination of in-
fected from vaccinated animals (DIVA). Furthermore, vac-
cine production required the production of large amounts
of infectious virus in cell culture, proper virus inactivation,
and formulation of the antigen with adjuvant, all of which
delayed production and added to the costs of producing
the vaccine. Importantly, inactivated virus vaccines may
not be suitable for the control of all serotypes of BTV as,
for example, serotype 25 cannot be propagated in cell cul-
ture [21]. To overcome these hurdles, our goal was to de-
velop and evaluate a generic vector vaccine in sheep, one
that would comply with the DIVA principle. Although
similar strategies using recombinant poxviruses (vaccinia,
goatpox, and canarypox viruses), herpesviruses, and virus-
like particles have been proven effective, we elected to
evaluate the vesicular stomatitis virus (VSV) replicon
system [22].
VSV is a non-segmented negative-strand RNA virus that
is known to trigger a robust humoral immune response in
many different host species [23]. Recombinant VSV vec-
tors have been employed for experimental vaccination of
mammals against a number of different pathogens such as
human papilloma virus, hepatitis C virus, or influenza A
virus [24]. A modified VSV vector in which the VSV glyco-
protein (G) gene was replaced by the influenza A virus
HA gene was shown to protect chickens from challenge
infection with highly pathogenic avian influenza viruses
[25,26]. This vector was propagated to high titers on
helper cells providing the VSV G protein in trans and was
able to infect a broad spectrum of different cell types. Due
to the autonomous replication of the viral RNA, high-levelexpression of recombinant antigens was achieved. How-
ever, due to the deletion of the VSV G protein gene,
VSVΔG vectors are restricted to a single round of in-
fection, contributing to their excellent biosafety profile.
These novel vector vaccines were effective even though
adjuvants were not employed [25,26].
In this study, propagation-incompetent VSVΔG vec-
tors expressing the BTV-8 outer capsid proteins VP2 or
VP5, or a combination of both, were generated. The
expression of recombinant BTV antigens was studied
and the immune response in sheep assessed. Immunized
sheep were then infected with virulent BTV-8 and mo-
nitored for viremia, clinical symptoms, and antibody
production. The DIVA principle was assessed using a
commercially available VP7-based competitive ELISA.Materials and methods
Cells
BHK-21 cells were obtained from the German Cell Culture
Collection (DSZM, Braunschweig, Germany) and grown
in Earle’s minimal essential medium (MEM; Life Tech-
nologies, Carlsbad, CA, USA) supplemented with 5% fetal
bovine serum (FBS; Biowest Nuaillé, France). BHK-G43, a
transgenic BHK-21 cell clone expressing the VSV G pro-
tein in a regulated manner, was maintained as described
previously [27]. Vero cells (C1008) were purchased from
the American Type Culture Collection (Manassas, VA,
USA) and maintained in Glasgow’s minimal essential
medium (GMEM; Life Technologies) supplemented with
5% FBS.Viruses
A German BTV-8 isolate (from 2008) was kindly provided
by Bernd Hoffmann (FLI, Riems, Germany). A French iso-
late of BTV-1 was obtained from The Pirbright Institute
(Pirbright, UK). Virus stocks were titrated on Vero cells.
Virus infection was monitored taking advantage of the
cytopathic effect apparent at day 5 post infection (pi).
Infectious virus titres were calculated according to the
Spearman-Kärber method and expressed as 50% tissue
culture infectious doses per mL (TCID50/mL).
In order to obtain virulent BTV-8 for challenge expe-
riments, two adult BTV-seronegative Poll Dorset sheep
were inoculated intravenously using erythrocytes pre-
pared from a BTV-8 viremic calf. This virus was ori-
ginally isolated in 2008 in Gummersbach, Germany.
Following infection, blood was collected at daily inter-
vals and analyzed for the presence of viral RNA by RT-
qPCR [28]. The sheep were euthanized at day 5 pi, when
a quantification cycle (Cq) value of 18 was determined in
blood by RT-qPCR. Blood was collected from the ani-
mal, erythrocytes were washed and suspended in PBS,
and frozen at −70 °C.
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Codon-optimized cDNA of VP2 (GenBank accession
number AM498052) and VP5 (GenBank accession num-
ber AM498056) of the BTV-8 strain NET2006/04 was
synthesized by GenScript (Piscataway, NJ, USA). For gen-
eration of recombinant VSV, the BTV-8 genes were
inserted into the plasmid pVSV* using MluI and BstEII re-
striction sites upstream and downstream of the fourth
transcription unit, thereby replacing the VSV G gene [25].
The resulting plasmids were designated pVSV*ΔG(VP2)
and pVSV*ΔG(VP5), respectively. For generation of a dual
antigen expression vector, the VP5 cDNA was inserted
into pVSV*ΔG(VP2) using XhoI and NheI restriction sites
located upstream and downstream of the fifth trans-
cription unit, thereby replacing the green fluorescent pro-
tein (GFP) gene. The resulting plasmid was designated
pVSVΔG(VP2,VP5). For expression of a modified VP5
containing a short peptide epitope at the C terminus, the
VP5 gene without its Stop codon was inserted into the
pCMV-3Tag-3 plasmid vector (Agilent Technologies, Inc.,
Santa Clara, CA, USA) upstream of and in frame with a
triple FLAG epitope (DYKDDDDK)-coding region, which
was followed by a Stop codon. The VP5-FLAG open rea-
ding frame was then amplified by PCR and inserted into
either the fourth transcription unit of pVSV*ΔG or the
fifth transcription unit of pVSV*ΔG(VP2). The resul-
ting plasmids were designated pVSV*ΔG(VP5-FLAG)
and pVSVΔG(VP2,VP5-FLAG), respectively. VSV replicon
particles (VRPs) were generated and propagated on BHK-
G43 helper cells as described previously [29].
Recombinant VSV*ΔG(VP2), VSV*ΔG(VP5), VSV*ΔG
(VP5-FLAG), and VSV*ΔG [25] were titrated on BHK-21
cells taking advantage of the GFP reporter protein. Infec-
tious titers were calculated and expressed as fluorescence-
forming units per milliliter (ffu/mL). For detection of
VSVΔG(VP2,VP5) and VSV*ΔG(VP2,VP5-Flag), infected
cells were fixed with PBS containing 3% paraformaldehyde
for 20 min at room temperature, washed with PBS con-
taining 0.1 M (w/v) glycine, and permeabilized with 0.25%
(v/v) of Triton-X100. The cells were incubated with rabbit
anti-VSV serum and subsequently with a goat anti-rabbit
horseradish peroxidase conjugate (dilution 1:500 in PBS;
DAKO; Glostrup, Denmark) and finally stained with AEC/
H2O2 substrate.
Immunofluorescence analysis
Vero cells grown on 12-mm-diameter cover slips were in-
oculated for 90 min with either VSV*ΔG, VSV*ΔG(VP2),
VSV*ΔG(VP5-FLAG), VSVΔG(VP2,VP5) or pVSVΔG
(VP2,VP5-FLAG) using a multiplicity of infection (MOI)
of 3. At 8 hours pi, the cells were fixed with 3% parafor-
maldehyde for 20 min, washed with PBS containing 0.1 M
(w/v) glycine, and incubated with PBS containing 0.25%
(v/v) Triton X-100 for 5 min to permeabilize the plasmamembrane. The cells were incubated with a monoclonal
antibody directed against either VP2 (clone 13C10, diluted
1:10; kindly provided by Dr Malte Dauber, FLI Riems,
Germany) or a monoclonal antibody directed against the
FLAG epitope (clone M2, diluted 1:50; Sigma-Aldrich,
Deisenhofen, Germany) and subsequently with an anti-
mouse IgG-Alexa 546 conjugate (dilution 1:500; Life
Technologies, Carlsbad, CA, USA). Finally, the cells were
washed with distilled water and embedded in Mowiol
4–88 (Sigma-Aldrich, Deisenhofen, Germany) mounting
medium. The cells were analyzed using a Leica TCS-SL
spectral confocal microscope (CFM) and Leica LCS soft-
ware (Leica Microsystems AG, Glattbrugg, Switzerland).
To analyze sera from immunized sheep for the presence
of virus-specific antibodies, Vero cells were grown on
12-mm-diameter cover slips, infected with BTV-8 (MOI
of 1), and incubated for 48 h with medium containing
0.9% (w/v) methylcellulose. The cells were fixed, perme-
abilized, and incubated with serum (diluted 1:100 in PBS
with 1% BSA) from immunized sheep and subsequently
with anti-sheep IgG-Alexa 488 conjugate (dilution 1:500
in PBS; Life Technologies, Carlsbad, CA, USA). Fluores-
cence microscopy was performed using an Axio Observer
Z1 inverted microscope (Zeiss, Jena, Germany).
Animal experiments
Animal trials were performed in compliance with the
Swiss Animal Protection Law and approved by the Animal
Welfare Committee of the Canton of Berne (authorization
number 112/12). Twenty-four white Swiss White Alp
sheep (12 to 24 months old), that were tested seronegative
for BTV by ELISA (see below), were immunized intra-
muscularly with 2.5 mL of cell culture supernatant con-
taining either VSV*ΔG, VSV*ΔG(VP2), VSV*ΔG(VP5), or
VSVΔG(VP2,VP5), respectively. Three weeks (day 21)
after the primary immunization (day 0), the animals re-
ceived the same vaccine a second time. At day 42, 4 mL of
erythrocyte suspension from BTV-8 infected viremic
sheep (see above) were injected into the animals intraven-
ously. Following inoculation, the animals were surveyed
daily for clinical signs of disease which were scored ac-
cording to a modified clinical scoring system [30]. All sur-
viving animals were euthanized at day 14 post challenge.
Serological tests
Serum neutralization tests were performed as described
previously [31]. Briefly, immune sera (heat-inactivated
at 56 °C for 30 min) were serially diluted in FBS-free tis-
sue culture medium and incubated for 1 h at 37 °C with
40 TCID50/50 μL. Vero cells were added and incubated
at 37 °C for 5 days. If not neutralized by immune serum,
BTV caused a cytopathic effect 3 to 5 days pi. Neu-
tralizing antibody titres were calculated according to
the Spearman-Kärber method. For detection of VSV-
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Indiana) expressing GFP was used [32]. A polyclonal
anti-VSV serum was used as reference. For detection of
VP7-specific serum antibodies, a commercially available
competitive ELISA was used according to the manufac-
turer’s protocol (VMRD, Pullman, USA).RNA extraction and quantitative RT-PCR
Total RNA was extracted from whole blood samples
using the Ambion MagMAX blood RNA isolation kit
(Applied Biosystems, Foster City, California, USA) and
stored at −70 °C. For detection of viral RNA, a reverse
transcriptase quantitative PCR (RT-qPCR) based on the
amplification of segment 10 was performed in dupli-
cates using in vitro-transcribed GFP RNA as internal
control [28].Statistical analysis
Statistical significance (p < 0.05) was considered using a
two-way ANOVA and multiple comparisons were assessed
using GraphPad Prism6 Sidak’s post-hoc test.Figure 1 Genome maps and analysis of recombinant protein expressi
nucleoprotein (N), phosphoprotein (P), matrix protein (M), and the large RN
GFP gene (denoted by *). VSV*ΔG(VP2) and VSV*ΔG(VP5) express either VP2
is expressed from an additional transcription unit downstream of VP2. VSVΔ
position. (B) Immunofluorescence analysis of Vero cells 8 hpi with either VS
(VP2,VP5-FLAG), or VSV*ΔG. In the upper panel, expression of VP2 is indicat
13C10). In the lower panel, expression of VP5 is indicated by red fluorescen
GFP is indicated by green fluorescence. Scale bar represents 19 μm.Results
Generation of recombinant RNA replicon particles
expressing BTV antigens
We previously generated a propagation-incompetent VSV
vector by replacing the VSV glycoprotein (G) gene in the
fourth transcription unit of the viral genome with genes
encoding influenza virus antigens [25]. This vector con-
tained an additional transcription unit at position 5, which
was used to express the green fluorescent protein (GFP).
Based on this vector platform we generated the recombin-
ant viruses VSV*ΔG(VP2) and VSV*ΔG(VP5) containing
the VP2 and VP5 genes of BTV-8 in the fourth transcrip-
tion unit of the vector (Figure 1A). A vector expressing
both antigens, VSV*ΔG(VP2,VP5), was constructed by re-
placing the GFP gene in the fifth position of VSV*ΔG
(VP2) by the VP5 gene of BTV-8. VSV*ΔG(VP5-FLAG)
and VSVΔG(VP2,VP5-FLAG) contained a triple FLAG
epitope at the C terminus of VP5 and were generated
to ease detection of this antigen. Recombinant VSV*ΔG
served as control vector as it did not express any BTV
antigen [25]. All recombinant viruses were propagated on
helper cells providing the VSV glycoprotein G in trans,on. (A) Genome maps of recombinant VSV. VSV*ΔG encodes for
A polymerase (L). The VSV glycoprotein (G) has been replaced by the
or VP5 antigen of BTV-8 from the fourth transcription unit while GFP
G(VP2,VP5) expresses VP2 from the fourth and VP5 from the fifth
V*ΔG(VP2), VSVΔG(VP2,VP5), VSV*ΔG(VP5), VSV*ΔG(VP5-FLAG), VSVΔG
ed by red fluorescence using a monoclonal anti-VP2 antibody (clone
ce using a monoclonal anti-FLAG (clone M2) antibody. Expression of
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tious units per mL of cell culture supernatant.
The expression of recombinant BTV-8 proteins was de-
termined by immunofluorescence staining of Vero cells
6 hours pi with recombinant VSV. A BTV-8 VP2-specific
monoclonal antibody reacted with cells that were infected
with VSV*ΔG(VP2) or VSV*ΔG(VP2,VP5), whereas cells
infected with VSV*ΔG(VP5) or VSV*ΔG were not recog-
nized (Figure 1B). Since a VP5-specific antibody was not
available, expression of VP5 was confirmed using a modi-
fied antigen with a triple FLAG epitope at the C terminus.Figure 2 Antibody responses of immunized sheep.
(A) Immunofluorescence analysis of BTV-8 infected cells. Vero cells
were infected with an MOI of 1 and further incubated for 24 h at 37 °C.
The cells were fixed, permeabilized, and incubated with immune sera
from sheep immunized twice with the indicated VRPs. The primary
antibodies were detected with anti-sheep IgG-Alexa 546 conjugate
(red fluorescence). Scale bar represents 24 μm. (B) Detection of
BTV-8 neutralizing serum antibodies. Sera were prepared from
VRP-immunized sheep (group size n= 6) at day 0 (first vaccination), day
21 (second vaccination), and day 42 (three weeks after the second
immunization). Neutralization of virus was estimated 3 to 5 dpi according
to the development of CPE. Neutralizing titres were calculated and
expressed as ND50/100 μL. Values equal to or lower than 2 were
regarded negative.The monoclonal anti-FLAG antibody reacted specifically
with Vero cells infected with VSV*ΔG(VP5-FLAG) and
VSVΔG(VP2,VP5-FLAG) but not with VSV*ΔG-infected
cells (Figure 1B). Taken together, these data show that in-
fection of Vero cells with virus replicon particles readily
led to expression of BTV-8 antigens, both VP2 and VP5.
However, infectious VSV was not produced by the cells
since the VSV G protein was not expressed. Therefore, we
refer to the recombinant VSV vectors as virus replicon
particles (VRP).
Analysis of antibody responses in VRP-immunized sheep
To evaluate the immunogenicity of recombinant VRPs in
a natural BTV host, 12 to 24 month-old Swiss White Alp
sheep were divided into 4 groups of 6 animals each and
immunized with cell culture supernatant containing at
least 1 × 108 infectious units of either VSV*ΔG(VP2),A
B
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Figure 3 Clinical signs of disease in BTV-8 infected sheep.
(A) The clinical symptoms of vaccinated sheep groups (n = 6) were
monitored daily following infection with a virulent BTV-8 strain and
scored as described in Materials and Methods. Mean values and
standard deviations are indicated. (B) The rectal body temperature
of the infected animals was determined daily for a total period of
14 days. Body temperatures of up to 39.5 °C were regarded as
normal, temperatures between 39.5 °C and 40.5 °C as moderately
elevated, and temperatures higher than 40.5 °C were defined as high
fever (temperature limits indicated by dashed lines). Mean values
and standard deviations are indicated.
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were not employed. After 3 weeks, the animals were im-
munized a second time with the same VRPs. No adverse
side effects following vaccination were observed. Sera
were analyzed 3 weeks after the second immunization for
the presence of BTV-specific antibodies by immunofluor-
escence. Sera from sheep immunized with either VSV*ΔG
(VP2), VSV*ΔG(VP5) or VSVΔG(VP2,VP5) reacted spe-
cifically with BTV-8 infected cells, indicating that all
recombinant antigens were immunogenic and induced the
production of BTV-8 specific antibodies (Figure 2A). Sera
from VSV*ΔG-immunized sheep did not react.
The sheep immune sera were tested for neutralizing
activity against BTV-8. Pre-immune sera did not show
any neutralizing activity confirming that the animals had
no pre-existing immunity to BTV-8 (Figure 2B). Sera
collected 3 weeks after the first immunization showed
limited neutralizing activity but only at the highest
serum concentration used (1:4). However, 3 weeks after
the second vaccination with VSV*ΔG(VP2) or VSVΔGA
DC
B
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Figure 4 Determination of viral RNA loads in blood of BTV-8 challeng
vaccinated with (A) VSV*ΔG, (B) VSV*ΔG(VP5), (C) VSV*ΔG(VP2,VP5), and (D
was extracted from whole blood samples and RT-qPCR was performed to d
fluorescence signals were expressed as 50-Cq for all 24 animals (numbered(VP2,VP5), all but one of the animals in the VSV*ΔG
(VP2) group had developed high neutralizing antibody
titres against BTV-8. The same sera did not neutralize
BTV-1 or the VSV vector (data not shown). Sheep im-
munized with either VSV*ΔG or VSV*ΔG(VP5) did not
develop BTV-8 neutralizing antibodies. Taken together,
these data demonstrate that although recombinant VRPs
induced antibodies against both VP2 and VP5, only anti-
VP2 antibodies showed BTV-8 neutralizing activity
in vitro.
VRPs expressing VP2 antigen protect sheep from
challenge with pathogenic BTV-8
To evaluate the capacity of recombinant VRP vaccines to
induce protective immunity against pathogenic BTV-8,
sheep were inoculated intravenously 3 weeks after the
second immunization with erythrocyte suspension from a
BTV-8 viremic sheep (Cq value of 18). Sheep immunized
with VSV*ΔG or VSV*ΔG(VP5) showed characteristic signs
of bluetongue disease beginning at day 5 pi (Figure 3A).VSV*ΔG(VP2)
VSV*ΔG(VP5)
Days post infection
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ed sheep. Blood was collected from the animal groups (n = 6)
) VSV*ΔG(VP2) every second day after infection with BTV-8. Total RNA
etermine viral RNA load. The quantification cycles (Cq) for detection of
#1 to #24).
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Figure 5 Detection of VP7 antibodies in serum of immunized
sheep before and after challenge infection with BTV-8.
Blood was collected from sheep three weeks after the second
immunization (prior to challenge infection with BTV-8) and two weeks
after challenge by the end of the experiment. Serum antibodies
specific for the VP7 antigen of BTV were detected using a commercially
available competitive ELISA. Optical density was recorded at 620 nm
and expressed as percentage OD620 relative to an internal negative
control. OD620 values < 50% were considered positive, values between
50% and 60% were regarded as doubtful, and values higher than 60%
as negative (thresholds indicated by dashed lines).
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lethargy. Three animals from the VSV*ΔG group and two
animals from the VSV*ΔG(VP5) group were euthanized
for humane reasons at days 12 and 13 pi, respectively, as
they developed severe lung edema and respiratory distress.
All animals of the two groups developed high fever, which
peaked at day 8 after infection (Figure 3B). In contrast, all
animals immunized with VSVΔG(VP2,VP5) and 5 out of 6
animals immunized with VSV*ΔG(VP2) did not show any
clinical signs of disease (Figure 3A) and had normal rec-
tal temperature (<39.5 °C) throughout the experiment
(Figure 3B). These differences were significant between 7
and 11 dpi in the clinical scoring and between 5 and 9 dpi
for body temperature. The single animal in the VP2 group,
which did not develop a detectable neutralizing antibody
titre to BTV (see Figure 2B), showed moderate clinical
signs of disease and fever for three days.
The capacity of the vaccine-induced immune response
to suppress viremia was evaluated by determining viral
RNA loads in blood by quantitative RT-qPCR (Figure 4).
Animals immunized with either VSV*ΔG or VSV*ΔG
(VP5) had high levels of viral RNA in blood, starting from
day 2 post challenge and lasting until the end of the ex-
periment at day 14, whereas BTV RNA was not detected
in the blood of the 6 sheep immunized with VSVΔG(VP2,
VP5). Likewise, 5 out of 6 sheep immunized with VSV*ΔG
(VP2) did not develop any viremia. Thus, recombinant
VRPs expressing VP2 alone or in combination with VP5
conferred protective immunity in sheep that prevented
both viremia and development of disease.
VP7 antibodies used for differentiation of infected from
vaccinated animals
At day 14 after infection, the animals were euthanized
and sera tested for the presence of VP7-specific anti-
bodies using a commercially available competitive ELISA
(Figure 5). All animals seroconverted following challenge
infection irrespective of the vaccine group tested, indi-
cating that even in protected animals (groups VSV*ΔG
(VP2) and VSV*ΔG(VP2,VP5)) limited replication of
challenge virus must have occurred, which was sufficient
to trigger an immune response against VP7. In contrast,
all immunized sheep were tested negative for VP7 anti-
bodies prior to infection, indicating that the VRP vaccine
fully complied with the DIVA principle.
Discussion
The BTV outer capsid proteins VP2 and VP5 provide
potential targets for neutralizing antibodies with all neu-
tralizing epitopes recognized to date residing on VP2.
The present study has demonstrated that recombinant
VSV replicon particles expressing the VP2 protein of
BTV-8 induce the production of serotype-specific neu-
tralizing antibodies that protect sheep from disease andviremia following challenge infection with BTV-8. Our
data confirm that immunization with VP2 alone is suffi-
cient to induce a protective immune response in vac-
cinated animals [14,33,34]. VP5 has been reported to
enhance the protective immune response if present in
the vaccine along with VP2 [16,35]. Employing a canary-
pox virus vector expressing VP2 and VP5 of BTV-17,
protection in sheep was achieved, but the relative contri-
butions of VP2 and VP5 to protection have not been ad-
dressed [36]. In a recent study, expression of both VP2
and VP5 by a recombinant equine herpesvirus vector
was necessary to protect mice against BTV-8 infection,
whereas VP2 alone was not fully protective [37]. In our
study, VRP co-expressing VP2 and VP5 did not induce
higher neutralizing antibody titers than VRP expressing
VP2. However, one animal in the VSV*ΔG(VP2) group
did not develop neutralizing antibodies and was not pro-
tected, whereas all animals in the VSV*ΔG(VP2,VP5)
group remained completely healthy following challenge
with BTV-8. The question whether this higher protec-
tion rate is attributable to the co-expression of VP2 and
VP5 should be addressed by additional experiments with
a larger number of animals. A critical parameter for the
efficacy of vector vaccines could be the level of expres-
sion and conformation of the recombinant VP2 antigen.
If expression levels are low, the proportion of properly
folded VP2 might increase in the presence of VP5 given
their extensive conformational interaction [13]. How-
ever, if high expression levels of VP2 are achieved with a
Kochinger et al. Veterinary Research 2014, 45:64 Page 8 of 9
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VP2 might be sufficient to induce neutralizing anti-
bodies. Antibodies directed to VP5 may not have neu-
tralizing properties on their own, probably because this
antigen is not readily accessible for antibodies on the
virion surface. Accordingly, the VP5 primary sequence is
much more conserved than that of VP2, indicating that
VP5 is subject to less immune pressure.
Conventional BTV vaccines have to be properly inacti-
vated and formulated with adjuvants before they can be
applied to animals once (sheep) or twice (cattle). Neutra-
lizing antibodies were shown to persist up to four years
after immunization [38,39]. The present VRP vaccine did
not depend on adjuvants to induce a protective immune
response in sheep, probably because this RNA virus vector
is cytotoxic and provides sufficient innate signaling to
stimulate the immune system. Any adverse side effects
which could be caused by adjuvants [40] are thereby eli-
minated. However, significant levels of neutralizing serum
antibodies were detected only after the animals had been
vaccinated with the VRP vaccine twice. Additional studies
are required to determine the protective effect of a single
immunization. In addition, it will be interesting to see for
how long VRP-induced neutralizing antibodies will persist
in sheep.
Despite their efficacy, live-attenuated BTV vaccines have
inherent disadvantages including transmission to insect
vectors, lack of attenuation, reassortment of gene seg-
ments with field strains of the virus, and potential to cross
the placenta to cause reproductive losses and teratogenic
effects [41]. In contrast, the propagation-defective VRP
vaccine does not cause disease nor will it be able to revert
to virulence. As the G protein, the major antigen of VSV,
is not expressed by VRPs, neutralizing antibodies against
the viral vector are not induced. Accordingly, VRP vac-
cines are effective when used repeatedly [25,26,42]. Since
antibodies directed to VSV G protein are lacking, vac-
cinated animals will appear seronegative in VSV diagnos-
tic tests [43].
Vector vaccines are superior to conventional vaccines,
since they can serve as marker vaccines [22]. The VRP vac-
cine did not contain the VP7 antigen and therefore allowed
the discrimination of infected from vaccinated animals
using a commercially available VP7 ELISA. In contrast,
conventional (inactivated) BTV vaccines, live-attenuated
and propagation-defective BTV vaccines [44,45] do not
comply with the DIVA principle. This has complicated the
serological surveillance of BTV in those European countries
that implemented a vaccination campaign to control the
BTV-8 outbreak in 2006. Moreover, the inability to discri-
minate between infected and vaccinated animals had a sig-
nificant impact on economy due to restrictions on animal
trade [46]. The recombinant replicon particles eliminate
this problem as they can be used as marker vaccines.Currently, there is no universal vaccine available that
would protect against all 26 known serotypes of BTV. The
VRP technology is not restricted to BTV-8 antigens but
may be used to express VP2 antigen of other BTV sero-
types as well. Thus, in case a new serotype emerges in a
non-endemic region, a recombinant VRP vaccine mat-
ching this serotype could be rapidly produced and used
for emergency vaccination. This should be particularly
valuable for BTV strains for which inactivated vaccines are
not readily available because the corresponding viruses do
not propagate well in cell culture. Furthermore, this
generic vaccine platform may be also employed to protect
horses against infection with African horse sickness virus,
an orbivirus of which 9 different serotypes are known.
In summary, this study has demonstrated that propa-
gation-incompetent VSV replicon particles can efficiently
protect a natural host against bluetongue disease and
viremia. This safe and adjuvant-free vaccine technology
complies with the DIVA principle, can be easily adapted
to other serotypes and viruses, and is rapidly available in
case of an emerging BTV outbreak.
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